Welcome to the Indian Journal of Respiratory Care, a premier platform dedicated to advancing research and clinical practices in the field of respiratory health. Published by JAYPEE BROTHERS MEDICAL PUBLISHERS PVT LTD, this journal has established itself as a crucial resource for researchers, healthcare professionals, and educators since embracing an Open Access model in 2012, ensuring maximum visibility and accessibility of vital research findings. The journal aims to disseminate high-quality articles encompassing a wide range of topics, including but not limited to, respiratory diseases, pulmonary care, and innovative treatment approaches. With its commitment to fostering collaboration and knowledge exchange, the Indian Journal of Respiratory Care is poised to make a significant impact in the ever-evolving landscape of respiratory medicine. As the field continues to grow, this journal serves as an essential touchpoint for those invested in enhancing patient care and outcomes.

The Canadian Respiratory Journal is a prominent peer-reviewed publication dedicated to advancing knowledge in the field of pulmonary and respiratory medicine. Published by HINDAWI LTD and based in Egypt, this journal has been an Open Access platform since 1994, ensuring broad dissemination of vital research findings to a global audience. With an ISSN of 1198-2241 and an E-ISSN of 1916-7245, the journal plays a significant role in shaping respiratory health discussions, evidenced by its 2023 category rankings of Q2 in Medicine (miscellaneous) and Q3 in Pulmonary and Respiratory Medicine. The journal consistently publishes high-quality research, reviews, and clinical guidelines that resonate with practitioners, researchers, and students alike. It serves as an essential resource for those seeking to stay at the forefront of developments in respiratory health, reflecting its commitment to enhancing practice and informing policy while recognizing its place in this vital medical field.

Annals of Thoracic Medicine is a prominent open-access journal, published by Wolters Kluwer Medknow Publications, focusing on the critical fields of cardiology, pulmonary and respiratory medicine, and surgery. With an ISSN of 1817-1737 and an E-ISSN of 1998-3557, this journal aims to disseminate cutting-edge research, clinical findings, and innovative practices that can significantly impact the health outcomes of patients dealing with thoracic diseases. Since its inception in 2006, it has established itself as a reputable source of knowledge, achieving Q2 quartile rankings in 2023 across its main categories. Currently ranked #126 in Medicine & Surgery and exhibiting a growing SCOPUS percentile, the journal plays an essential role in advancing the understanding and treatment of thoracic conditions. Open access options ensure that research is readily available to a global audience, facilitating collaboration and knowledge sharing among researchers, healthcare professionals, and students in the field.

The Eurasian Journal of Pulmonology is a premier open access journal dedicated to advancing the field of respiratory medicine and thoracic diseases. Published by KARE PUBL since 1999, the journal serves as an invaluable platform for researchers, clinicians, and students, facilitating the dissemination of innovative research findings and clinical practices. With an emphasis on high-quality and peer-reviewed articles, it aims to foster collaboration and knowledge sharing among professionals in the pulmonology community. Although the journal’s precise impact factor is currently not specified, its commitment to openness and accessibility ensures a broad reach and engagement with vital research, making it a critical resource for those in the academic and medical fields. The journal is based in Istanbul, Turkiye, further enriching its contributions to the Eurasian medical landscape and global health discourse.

Welcome to Pulmonary Pharmacology & Therapeutics, a leading journal dedicated to the dissemination of innovative research and insights in the fields of pulmonary medicine and pharmacology. Published by Academic Press Ltd - Elsevier Science Ltd, this journal has made significant contributions to the academic community since its inception in 1997, with an ongoing commitment to relevant advancements projected through to 2024. With reputable Q2 rankings across vital categories including Biochemistry (medical), Medicine (miscellaneous), Pharmacology (medical), and Pulmonary and Respiratory Medicine, Pulmonary Pharmacology & Therapeutics is ranked in the top tier of its field, reflecting its impact on the discipline as evidenced by its Scopus rankings. Researchers, healthcare professionals, and students alike can access a wealth of high-quality articles that address the complexity of pulmonary diseases and therapeutic strategies, supporting research and clinical practice alike. Join the vibrant community contributing to this essential field and explore the latest findings that can drive change in patient care and therapeutic effectiveness.

Respiratory Investigation is a leading peer-reviewed journal published by Elsevier, dedicated to advancing the field of Pulmonary and Respiratory Medicine. Since its inception in 2012, the journal has grown to become a vital resource for researchers, clinicians, and students alike, providing a platform for high-quality research articles, reviews, and clinical studies. With a commendable impact factor and ranked in the Q2 category of Scopus' 2023 metrics, it stands at rank #57 out of 155 in its field, illustrating its importance and influence within the academic community. Although the journal operates on a subscription basis, it remains committed to disseminating essential findings that enhance the understanding and treatment of respiratory diseases. Set against the innovative backdrop of the Netherlands, Respiratory Investigation not only serves as a conduit for scholarly exchange but also plays a critical role in shaping future research directions and clinical practices.

The Egyptian Journal of Chest Diseases and Tuberculosis is a premier Open Access journal published by Wolters Kluwer Medknow Publications, focusing on the latest advancements in the fields of respiratory diseases, pulmonary medicine, and tuberculosis management. With an ISSN of 0422-7638 and an E-ISSN of 2090-9950, this journal aims to disseminate high-quality research, reviews, and clinical insights that advance the understanding and treatment of chest diseases. Since its transition to Open Access in 2018, the journal has garnered increased visibility, enabling researchers across the globe to contribute and access valuable content without barriers. Situated in India, the journal is dedicated to bridging the gap between clinical practice and research, emphasizing the significance of innovative therapeutic strategies and public health approaches in combating respiratory illnesses. We invite researchers, healthcare professionals, and students to engage with our publications as we continue to foster knowledge and foster collaboration within the global medical community.

European Respiratory Review is a prestigious peer-reviewed journal published by EUROPEAN RESPIRATORY SOC JOURNALS LTD, specializing in the dynamic field of pulmonary and respiratory medicine. With an impact factor that places it among the top quartile journals in its category (Q1), as indicated by its impressive Scopus rank of #7 out of 155, it serves as a critical platform for disseminating high-quality research and innovative reviews in the field. As an Open Access journal since 2005, it ensures that cutting-edge findings are readily available to a global audience, promoting greater transparency and collaboration within the academic community. Published from Switzerland, European Respiratory Review covers a broad spectrum of topics from clinical advancements to emerging trends, making it an essential resource for researchers, healthcare professionals, and students committed to advancing respiratory health. The journal's history, dating back to 1992, reflects a steadfast commitment to fostering scholarly exchange and driving forward the frontiers of knowledge within respiratory medicine.

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.